197 related articles for article (PubMed ID: 15613240)
1. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic co-operation in beta-cell tumorigenesis.
Pelengaris S; Khan M
Endocr Relat Cancer; 2001 Dec; 8(4):307-14. PubMed ID: 11733227
[TBL] [Abstract][Full Text] [Related]
3. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
4. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW
Nature; 2004 Oct; 431(7012):1112-7. PubMed ID: 15475948
[TBL] [Abstract][Full Text] [Related]
5. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
Boxer RB; Jang JW; Sintasath L; Chodosh LA
Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.
Pelengaris S; Khan M; Evan GI
Cell; 2002 May; 109(3):321-34. PubMed ID: 12015982
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis.
Fontanière S; Tost J; Wierinckx A; Lachuer J; Lu J; Hussein N; Busato F; Gut I; Wang ZQ; Zhang CX
Endocr Relat Cancer; 2006 Dec; 13(4):1223-36. PubMed ID: 17158767
[TBL] [Abstract][Full Text] [Related]
9. Conditional inactivation of Myc impairs development of the exocrine pancreas.
Nakhai H; Siveke JT; Mendoza-Torres L; Schmid RM
Development; 2008 Oct; 135(19):3191-6. PubMed ID: 18715949
[TBL] [Abstract][Full Text] [Related]
10. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
11. Oncogene addiction: sometimes a temporary slavery.
Jonkers J; Berns A
Cancer Cell; 2004 Dec; 6(6):535-8. PubMed ID: 15607957
[TBL] [Abstract][Full Text] [Related]
12. Omomyc expression in skin prevents Myc-induced papillomatosis.
Soucek L; Nasi S; Evan GI
Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
[TBL] [Abstract][Full Text] [Related]
13. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
14. Myc lacks E2F1's ability to suppress skin carcinogenesis.
Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
[TBL] [Abstract][Full Text] [Related]
15. Targeted expression of c-Myc in the epidermis alters normal proliferation, differentiation and UV-B induced apoptosis.
Waikel RL; Wang XJ; Roop DR
Oncogene; 1999 Aug; 18(34):4870-8. PubMed ID: 10490820
[TBL] [Abstract][Full Text] [Related]
16. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
17. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.
Lewis BC; Klimstra DS; Varmus HE
Genes Dev; 2003 Dec; 17(24):3127-38. PubMed ID: 14681205
[TBL] [Abstract][Full Text] [Related]
18. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
Lawlor ER; Soucek L; Brown-Swigart L; Shchors K; Bialucha CU; Evan GI
Cancer Res; 2006 May; 66(9):4591-601. PubMed ID: 16651409
[TBL] [Abstract][Full Text] [Related]
19. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
Arvanitis C; Felsher DW
Semin Cancer Biol; 2006 Aug; 16(4):313-7. PubMed ID: 16935001
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.
Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
Cancer Res; 2002 Jun; 62(11):3276-81. PubMed ID: 12036945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
